AUGELLO, MATTEO
 Distribuzione geografica
Continente #
NA - Nord America 2.570
AS - Asia 2.321
EU - Europa 1.766
SA - Sud America 228
AF - Africa 89
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.991
Nazione #
US - Stati Uniti d'America 2.483
IT - Italia 773
SG - Singapore 656
CN - Cina 626
VN - Vietnam 236
HK - Hong Kong 229
BR - Brasile 183
BD - Bangladesh 175
GB - Regno Unito 146
NL - Olanda 144
RU - Federazione Russa 134
FR - Francia 117
IN - India 113
DE - Germania 99
FI - Finlandia 81
SE - Svezia 73
CA - Canada 61
ES - Italia 58
ID - Indonesia 50
JP - Giappone 46
TR - Turchia 35
KR - Corea 33
AT - Austria 23
PL - Polonia 22
CI - Costa d'Avorio 20
IE - Irlanda 20
SA - Arabia Saudita 20
ZA - Sudafrica 19
TH - Thailandia 17
AR - Argentina 16
AU - Australia 16
MX - Messico 15
IR - Iran 14
DK - Danimarca 12
CH - Svizzera 11
IQ - Iraq 10
EG - Egitto 9
UA - Ucraina 9
NG - Nigeria 8
PH - Filippine 8
MY - Malesia 7
PT - Portogallo 7
CO - Colombia 6
CZ - Repubblica Ceca 6
EC - Ecuador 6
PK - Pakistan 6
UZ - Uzbekistan 6
ZW - Zimbabwe 6
KZ - Kazakistan 5
PE - Perù 5
AE - Emirati Arabi Uniti 4
CL - Cile 4
ET - Etiopia 4
IL - Israele 4
KE - Kenya 4
LT - Lituania 4
LV - Lettonia 4
NO - Norvegia 4
RO - Romania 4
TN - Tunisia 4
AZ - Azerbaigian 3
BE - Belgio 3
BJ - Benin 3
MA - Marocco 3
QA - Qatar 3
RS - Serbia 3
TW - Taiwan 3
UY - Uruguay 3
ZM - Zambia 3
AL - Albania 2
CR - Costa Rica 2
GH - Ghana 2
GR - Grecia 2
GT - Guatemala 2
JM - Giamaica 2
LK - Sri Lanka 2
LY - Libia 2
OM - Oman 2
PY - Paraguay 2
SV - El Salvador 2
BG - Bulgaria 1
BO - Bolivia 1
CY - Cipro 1
EE - Estonia 1
GY - Guiana 1
HR - Croazia 1
HU - Ungheria 1
JO - Giordania 1
KG - Kirghizistan 1
KH - Cambogia 1
MO - Macao, regione amministrativa speciale della Cina 1
MQ - Martinica 1
MT - Malta 1
MZ - Mozambico 1
NI - Nicaragua 1
NP - Nepal 1
PA - Panama 1
PS - Palestinian Territory 1
SC - Seychelles 1
SY - Repubblica araba siriana 1
Totale 6.989
Città #
Dallas 428
Singapore 345
Ashburn 328
Milan 226
San Jose 193
Hong Kong 192
Hefei 126
Los Angeles 110
Santa Clara 105
Baltimore 102
Beijing 102
Council Bluffs 89
Chicago 81
Ho Chi Minh City 75
New York 59
Chandler 55
Hanoi 55
Rome 55
Helsinki 50
Boardman 49
Buffalo 48
Southend 44
Bengaluru 43
Jakarta 38
Lauterbourg 37
Moscow 34
Frankfurt am Main 33
Austin 32
Guangzhou 30
Dos Hermanas 29
Seattle 29
Leiden 27
Galveston 26
São Paulo 26
The Dalles 26
Salt Lake City 25
Seoul 25
Tokyo 25
Bologna 24
Orem 23
Amsterdam 22
Munich 22
Naples 22
Montreal 21
Abidjan 20
Shanghai 20
Dublin 19
Istanbul 17
Vienna 17
Atlanta 16
Elk Grove Village 16
Haiphong 16
Houston 16
Lappeenranta 16
Turin 16
Warsaw 16
Florence 15
Toronto 15
Fairfield 14
Paris 14
Phoenix 14
Princeton 14
Riyadh 14
Da Nang 13
London 13
Palermo 13
Tampa 13
Cangzhou 12
Poplar 12
Turku 12
Boston 11
Chennai 11
Nuremberg 11
Phuket 11
Ferrara 10
Fremont 10
Bari 9
Brooklyn 9
Columbus 9
Coventry 9
Memphis 9
Sterling 9
Sydney 9
Washington 9
Cambridge 8
Genoa 8
Johannesburg 8
Nanjing 8
Shenzhen 8
Camaiore 7
City of London 7
Hải Dương 7
Monza 7
New Delhi 7
Newark 7
Pescara 7
Rio de Janeiro 7
Stockholm 7
Tianjin 7
Barcelona 6
Totale 4.181
Nome #
Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 552
Six-month immune responses to mRNA-1273 vaccine in combination antiretroviral therapy treated late presenter people with HIV according to previous SARS-CoV-2 infection 298
Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023 284
Primary HIV infection features colonic damage and neutrophil inflammation yet containment of microbial translocation 283
Long-Term Suppressive cART Is Not Sufficient to Restore Intestinal Permeability and Gut Microbiota Compositional Changes 266
Declining mortality rate of hospitalised patients in the second wave of the COVID-19 epidemics in Italy : Risk factors and the age-specific patterns 233
Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild–Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir 222
The importance of patients’ case-mix for the correct interpretation of the hospital fatality rate in COVID-19 disease 217
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort 212
Persistence of High Percentage of Peripheral Activated CD8+ T Cells Predict Cytologic HPV-Related Dysplasia in cART-Treated, HIV-Positive Subjects 212
Predictors of low ovarian reserve in cART-treated women living with HIV 210
Female gender is associated with long COVID syndrome : a prospective cohort study 205
Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects 198
Multi-layered deep immune profiling, SARS-CoV-2 RNAemia and inflammation in unvaccinated COVID-19 individuals with persistent symptoms 197
Association between SARS-CoV-2 RNAemia, skewed T cell responses, inflammation, and severity in hospitalized COVID-19 people living with HIV 192
Immunologic Interplay Between HIV/AIDS and COVID-19: Adding Fuel to the Flames? 189
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation 188
Association between SARS-CoV-2 RNAemia and dysregulated immune response in acutely ill hospitalized COVID-19 patients 177
Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced dimalsease: a trial emulation 175
Switching from intravenous to oral antibiotic therapy in the treatment of infective endocarditis: a case series and literature review of real-world data 158
Gut-dependent inflammation and alterations of the intestinal microbiota in individuals with perinatal HIV exposure and different HIV serostatus 150
Comparable gut mucosal breakdown and microbial translocation in severe COVID-19 with and without HIV infection 149
Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors 146
ORCHESTRA Delphi consensus: clinical management of SARS-CoV-2 infection in people with HIV 141
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort 135
A Quantitative Estimate of the Expected Shortening of the Median Isolation Period of Patients With COVID-19 After the Adoption of a Symptom-Based Strategy 134
Proportion of newly diagnosed persons with HIV with HIV-RNA greater than/equal to 500,000 copies/mL in 2018-2023 in Italy: data from the ICONA Foundation Cohort Study 130
Long-term immune responses to SARS-CoV-2 Omicron BA.4/5 mRNA booster in people living with HIV 124
Predicting humoral responses to primary and booster SARS-CoV-2 mRNA vaccination in people living with HIV: a machine learning approach 123
Should SARS-CoV-2 serological testing be used in the decision to deliver a COVID-19 vaccine booster? A pro-con assessment 122
Markers of T-cell dysfunction and not inflammaging predict the waning of humoral responses to SARS-CoV-2 mRNA booster vaccination in people with HIV 116
Incidence, risk factors and outcomes of healthcare-associated bacterial infections in COVID-19 patients receiving respiratory support: a retrospective cohort study 115
Failure of CD4+ T-cell recovery upon virally-effective cART : an enduring gap in the understanding of HIV+ immunological non-responders 115
Real-world use of cefiderocol as monotherapy or combination therapy for the treatment of Gram-negative bacterial infections: the multicentre retrospective CEFI-BAC study 115
SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio 114
HIV infection among adolescents and young adults in Italy: epidemiology, viro-immunological and treatment outcomes 114
Risk of COVID-19 in-hospital mortality in people living with HIV compared to general population according to age and CD4 strata: data from the Icona network 106
Renal microsporidiosis due to Encephalitozoon cuniculi in an HIV/AIDS patient with persistent fever and kidney injury 101
Three-Month cART Initiated During Primary HIV Does Not Correct the Structural, Immune, and Microbial Abnormalities within the Gastrointestinal Tract 73
Early Combination Antiretroviral Therapy Initiation During Primary HIV Infection Restricts HIV Reservoirs and Gut-Driven Inflammation but Fails to Rewire the Systemic Cytokine Landscape 71
ULTRA-LOW LEVEL SOLUBLE P24 IS ASSOCIATED WITH INFLAMMATION IN PEOPLE WITH HIV ON LONG-TERM VIROLOGICALLY SUPPRESSIVE ANTIRETROVIRAL THERAPY 44
Global, regional, and national burden of meningitis, its risk factors, and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 37
Age and viral replication, not vertical HIV acquisition, drive inflammation and T-cell dysfunction in heavily treatment experienced: data from the Prestigio Registry 37
Appropriate use of Doxy-PEP and inappropriate antibiotic self-medication for STI management: insights from a LGBTQIA+ survey in Italy 23
Astrocyte/monocyte activation and inflammation are associated with asymptomatic neurocognitive impairment in people with HIV on suppressive antiretroviral therapy 12
Risk of Developing Low-Level Viral Rebound Among People With HIV Receiving 2- or 3-Drug Regimens: A Case-Control Study Nested in the ICONA Cohort 1
Global burden of enteric infectious diseases, diarrhoeal diseases, and corresponding aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 1
ENDOCRINE AND METABOLIC ALTERATIONS IN AGING PLWH WITH LOW BONE MINERAL DENSITY 1
Current practices and challenges in the management of acute bacterial skin and skin structure infections (ABSSSI): results from an Italian multicenter survey with expert discussion 1
Totale 7.219
Categoria #
all - tutte 18.826
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.826


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216 0 0 0 0 0 0 0 0 0 0 0 6
2021/2022168 8 16 3 12 10 14 17 8 41 10 5 24
2022/2023274 12 13 14 18 22 41 19 24 33 3 42 33
2023/2024458 38 22 29 35 69 42 56 37 11 23 54 42
2024/20251.263 30 90 28 97 64 61 59 66 51 260 226 231
2025/20264.996 278 506 562 370 307 400 726 328 411 353 439 316
Totale 7.219